Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

sirexatamab (DKN-01)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Eli Lilly, Leap Therap

Drug class:

DKK1 protein inhibitor

Related drugs:

‹

›

DKK1 overexpression	Gastroesophageal Junction Adenocarcinoma	DKK1 overexpression	Gastroesophageal Junction Adenocarcinoma	DKN-01 Sensitive: B - Late Trials DKN-01 Sensitive : B	DKN-01 Sensitive: B - Late Trials DKN-01 Sensitive : B
DKK1 overexpression	Gastric Cancer	DKK1 overexpression	Gastric Cancer	DKN-01 Sensitive: B - Late Trials DKN-01 Sensitive : B	DKN-01 Sensitive: B - Late Trials DKN-01 Sensitive : B
DKK1 overexpression	Gastroesophageal Junction Adenocarcinoma	DKK1 overexpression	Gastroesophageal Junction Adenocarcinoma	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials pembrolizumab + DKN-01 Sensitive : C3	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials pembrolizumab + DKN-01 Sensitive : C3
DKK1 overexpression	Esophageal Squamous Cell Carcinoma	DKK1 overexpression	Esophageal Squamous Cell Carcinoma	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials pembrolizumab + DKN-01 Sensitive : C3	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials pembrolizumab + DKN-01 Sensitive : C3
DKK1 overexpression	Esophageal Adenocarcinoma	DKK1 overexpression	Esophageal Adenocarcinoma	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials pembrolizumab + DKN-01 Sensitive : C3	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials pembrolizumab + DKN-01 Sensitive : C3
DKK1 overexpression	Gastric Cancer	DKK1 overexpression	Gastric Cancer	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials pembrolizumab + DKN-01 Sensitive : C3	pembrolizumab + DKN-01 Sensitive: C3 – Early Trials pembrolizumab + DKN-01 Sensitive : C3
DKK1 overexpression	Endometrial Cancer	DKK1 overexpression	Endometrial Cancer	DKN-01 Sensitive: C3 – Early Trials DKN-01 Sensitive : C3	DKN-01 Sensitive: C3 – Early Trials DKN-01 Sensitive : C3
DKK1 overexpression	Esophageal Squamous Cell Carcinoma	DKK1 overexpression	Esophageal Squamous Cell Carcinoma	DKN-01 Sensitive: C3 – Early Trials DKN-01 Sensitive : C3	DKN-01 Sensitive: C3 – Early Trials DKN-01 Sensitive : C3
DKK1 overexpression	Esophageal Adenocarcinoma	DKK1 overexpression	Esophageal Adenocarcinoma	DKN-01 Sensitive: C3 – Early Trials DKN-01 Sensitive : C3	DKN-01 Sensitive: C3 – Early Trials DKN-01 Sensitive : C3
DKK1 overexpression	Gastroesophageal Junction Adenocarcinoma	DKK1 overexpression	Gastroesophageal Junction Adenocarcinoma	tislelizumab-jsgr + DKN-01 Sensitive: C3 – Early Trials tislelizumab-jsgr + DKN-01 Sensitive : C3	tislelizumab-jsgr + DKN-01 Sensitive: C3 – Early Trials tislelizumab-jsgr + DKN-01 Sensitive : C3
DKK1 overexpression	Ovarian Cancer	DKK1 overexpression	Ovarian Cancer	DKN-01 Sensitive: C3 – Early Trials DKN-01 Sensitive : C3	DKN-01 Sensitive: C3 – Early Trials DKN-01 Sensitive : C3
PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	tislelizumab-jsgr + DKN-01 Sensitive: C3 – Early Trials tislelizumab-jsgr + DKN-01 Sensitive : C3	tislelizumab-jsgr + DKN-01 Sensitive: C3 – Early Trials tislelizumab-jsgr + DKN-01 Sensitive : C3